Michael Ginsberg

Dr. Ginsberg is Director of Product Development at Angiocrine Bioscience. Following his post-doctoral fellowship at Rockefeller University, Michael undertook a post-doctoral position at Weill Cornel Medical College, where he was introduced into the world of vascular biology and hematopoiesis by Dr. Shahin Rafii. While under Dr. Rafii’s guidance, he gained tremendous knowledge and expertise in the study of endothelial cells, the predominant cell type that is necessary for the formation of the human vasculature. This work culminated in a seminal paper describing the manner in which amniotic cells could be reprogrammed into a functional, viable source of endothelial cells for potential therapeutic use. Through this work, Michael learned the intricacies involved in culturing and cultivating large quantities of endothelial cells in general, a process that would be necessary for their use in clinical applications. These experiences provided the foundation of his work that is now being done at Angiocrine Bioscience, as he is currently heading the manufacturing of GMP-grade E-CEL™ cells for their use in the clinic. Additionally, Michael is directing research aimed at identifying multiple indications for which these cells may have a beneficial therapeutic outcome. Dr. Ginsberg earned his Ph.D. from Columbia University, New York, and completed post-doctoral fellowships in the lab of Dr. James Darnell Jr at Rockefeller University, New York, and Shahin Rafii, MD at Weill Cornell Medicine.